Skip to main content
. 2018 Jan 19;103(5):840–848. doi: 10.3324/haematol.2017.180554

Figure 2.

Figure 2.

Response after ruxolitinib. Illustrative patient (UPN 601004). (A) Positron emission tomography (PET)-computer tomography (CT) frontal view. (B) PET-CT sagittal view. Partial response with allievation of B symptoms and blood inflammation was achieved 2 months after starting ruxolitinib. At month 6, the patient had slowly progressive disease but refused to stop ruxolitinib. CRP: C- reactive protein.